An improved method for quantification of extra domain A-containing cellular fibronectin (EDAcFN) in different body fluids

Detection of Soluble ED-A(+) Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling

Background and Aims. Fibronectin containing the extra domain A (ED-A⁺ Fn) was proven to serve as a valuable biomarker for cardiac remodeling. The study was aimed at establishing an ELISA to determine ED-A⁺ Fn in serum of heart failure patients. Methods. ED-A⁺ Fn was quantified in serum samples from 114 heart failure patients due to ischemic (ICM, n = 44) and dilated (DCM, n = 39) cardiomyopathy as well as hypertensive heart disease (HHD, n = 31) compared to healthy controls (n = 12). Results. In comparison to healthy volunteers, heart failure patients showed significantly increased levels of ED-A⁺ Fn (p < 0.001). In particular in ICM patients there were significant associations between ED-A⁺ Fn serum levels and clinical parameters, for example, increased levels with rising NYHA class (p = 0.013), a negative correlation with left ventricular ejection fraction (p = 0.026, r: −0.353), a positive correlation with left atrial diameter (p = 0.008, r: 0.431), and a strong positive correlation with systolic pulmonary artery pressure (p = 0.002, r: 0.485). In multivariate analysis, ED-A⁺ Fn was identified as an independent predictor of an ischemic heart failure etiology. Conclusions. The current study could clearly show that ED-A⁺ Fn is a promising biomarker in cardiovascular diseases, especially in heart failure patients due to an ICM. We presented a valid ELISA method, which could be applied for further studies investigating the value of ED-A⁺ Fn.

Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer

The extracellular matrix protein fibronectin (FN) contributes to the structural integrity of tissues as well as the adhesive and migratory functions of cells. While FN is abundantly expressed in adult tissues, the expression of several alternatively spliced FN isoforms is restricted to embryonic development, tissue remodeling and cancer. These FN isoforms, designated ED-A and ED-B, are frequently expressed by cancer cells, tumor-associated fibroblasts and newly forming blood vessels. Using a highly sensitive collagen-based indirect ELISA, we evaluated the correlation of urinary ED-A and ED-B at time of cystectomy with overall survival in patients with high-grade bladder cancer (BCa). Detectable levels of total FN as well as ED-A and ED-B were found in urine from 85, 73 and 51 % of BCa patients, respectively. The presence of urinary ED-A was a significant independent predictor of 2-year overall survival (OS) after adjusting for age, tumor stage, lymph node stage, and urinary creatinine by multivariable Logistic Regression (p = 0.029, OR = 4.26, 95 % CI 1.16-15.71) and improved accuracy by 3.6 %. Furthermore, detection of ED-A in the urine was a significant discriminator of survival specifically in BCa patients with negative lymph node status (Log-Rank, p = 0.006; HR = 5.78, 95 % CI 1.39-24.13). Lastly, multivariable Cox proportional hazards analysis revealed that urinary ED-A was an independent prognostic indicator of 5-year OS rate for patients with BCa (p = 0.04, HR = 2.20, 95 % CI 1.04-4.69). Together, these data suggest that cancer-derived, alternatively spliced FN isoforms can act as prognostic indicators and that additional studies are warranted to assess the clinical utility of ED-A in BCa.

Cellular and plasma fibronectin in the aqueous humour of primary open-angle glaucoma, exfoliative glaucoma and cataract patients

PURPOSE

To compare the concentrations of cellular fibronectin (cFN), plasma fibronectin (pFN), tenascin and calcitonin gene-related peptide (CGRP) in the aqueous humour in primary open-angle glaucoma (POAG), exfoliative glaucoma (EXFG) or cataract (control group).

METHODS

The concentrations were determined by enzyme-linked immunoassays in the aqueous humour of patients with EXFG (n = 26), POAG (n = 29) or cataract (control group, n = 13).

RESULTS

The pFN concentrations of the three patient groups differed significantly from each other (p = 0.0004 in a non-parametric analysis of variance). In multiple comparisons EXFG patients showed significantly higher pFN levels than POAG patients (p < 0.05) or cataract patients (p < 0.01). the cFN level was also significantly higher in EXGF patients than in POAG patients (p < 0.05) or cataract patients (p < 0.05). The pFN or cFN concentrations of the POAG group did not differ from those of the control group. Neither tenascin nor CGRP was detected in the aqueous humour of any of our patients.

CONCLUSIONS

The significantly higher aqueous humour pFN concentration in exfoliative glaucoma may be a consequence of disruption of the blood-aqueous barrier and may further add to an increased outflow resistance.

Modulation of integrin function inhibits HIV transmission to epithelial cells and fertilization

Integrin-mediated adhesive interactions are viewed in the context of HIV transmission to susceptible cells and fertilization. The ability of a low-molecular-weight non-peptide integrin modulator to inhibit HIV infection (virus-to-cell and cell-to-cell) and sperm-egg fusion is demonstrated. It is concluded that integrin-modulating substances offer significant promise as female-controlled means for preventing sexual transmission of HIV (whatever entity acts as HIV vector in semen and other penile secretions) and as female-controlled contraceptives.

Heparin-binding domain of human fibronectin binds HIV-1 gp120/160 and reduces virus infectivity

In vitro experiments indicate that components of the host present in body fluids may prevent the attachment of human immunodeficiency virus type 1 (HIV-1) to target cells. Fibronectin (Fn), a dimeric 440-kDa extracellular matrix adhesion protein, is secreted by mesenchymal cells and assembled into insoluble matrices. Fn exerts important effects on cell growth and differentiation through a number of discrete functional domains. Several microorganisms are known to bind Fn. We show that, under physiological conditions, HIV-1 gp120 and gp160 are capable of binding plasma and cellular Fn as well as laminin and vitronectin. Experiments were set up to analyze in detail the binding of HIV gp120 and gp160 to Fn. The gp120 and gp160 specifically recognize the C-terminal heparin-binding domain of Fn (Fn-CTHBD) with a calculated KD of 2.8 x 10(-7) M for gp160. Binding of gp160 to Fn-CTHBD is a saturable and specific process that is blocked by antibodies to Fn-CTHBD and by heparin and is inhibited to a minor extent by heparan sulfate and dextran sulfate. These observations suggest that gp120/160 specifically recognize the III15 repeat within Fn-CTHBD. Intact Fn and Fn-CTHBD strongly inhibit the interaction of gp120/160 with soluble CD4 and, under low serum conditions, are capable of neutralizing the infectivity of HIV-1 for CD4-positive T cells. Thus, Fn that is present in plasma and mucinous secretions may well affect HIV infectivity and virus distribution in vivo.